March 23, 2026
Given its ability to rapidly evolve new mutations and resist novel treatment regimens, drug-resistant tuberculosis (DR-TB) is an ever-present and growing threat to global health and TB management. For patients with DR-TB, delayed diagnosis often means prolonged illness, more intense treatments, and fewer options. In Johannesburg, South Africa, Miriam Bihala’s experience—18 months of treatment followed by years of recovery after a drug-resistant diagnosis—reflects a broader challenge: traditional testing methods can take months and offer limited insight when decisions are most urgent.
As part of the “Healthier Together” series, BBC Storyworks, the WHO Foundation, and Illumina are sharing the story of Bihala, a TB survivor; Professor Norbert Ndjeka of South Africa’s National TB Programme; and Professor Shaheed Vally Omar of the National TB Laboratory.
Researchers and clinicians recognize the power of next-generation sequencing to transform that reality. Next-generation sequencing detects drug resistance more quickly than culture-based testing and provides more details about resistance than conventional molecular tests. Beyond individual care, NGS strengthens public health efforts by uncovering transmission patterns and supporting more targeted programmatic interventions.
As collaborations between laboratories, clinicians, and health systems grow, sequencing is reshaping their approach to infectious disease research and management—delivering more detailed and faster answers. “Quicker answers mean people can start treatment sooner—not just to survive, but to keep their dignity and their hope,” Bihala told the BBC.
Read a Labroots article on countrywide DR-TB success stories.
Watch this video on ending DR-TB. #EndTB2030
Watch a TB webinar series to learn more about tuberculosis surveillance.
